Ultrarapid genomics for the critically ill

Ultrarapid Genomic Medicine to improve health management for critically ill patients at the ErasmusMC Sophia's Children's Hospital - Ultrarapid genomics for the critically ill

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57526

Enrollment

Registered

2025-05-02

Start date

2025-05-09

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital, familial and genetic disorders

Interventions

Experiences with ultrarapid genetic testing using Nanopore LR-GS

Eligibility

Age

No minimum to 64 Years

Inclusion criteria

Inclusion criteria: (Parents of) critically ill pediatric patients admitted to the Erasmus MC-Sophia Children's Hospital who underwent ultrarapid genetic testing using Nanopore LR-GS.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Time till diagnosis and impact on clinical decision-making and clinical consequences of ultrarapid genetic testing	—

Secondary

Measure	Time frame
Diagnostic yield, cost-effectiveness, psychological impact	—

Countries

Netherlands

Contacts

Public ContactVJM Verhoeven

Erasmus MC, Universitair Medisch Centrum Rotterdam

v.verhoeven@erasmusmc.nl0629633574

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)